Journal of Pharmaceutical and Biomedical Sciences

hsa-miR- 574-5p Down Regulates the Expression of CBR1 in A549 Cells and Enhances their Invasive Ability

Aijun Liu, Zhiming Liang, Jianping Zhang

Abstract


Objective To explore the impact of CBR1expression on A549 cell proliferation and invasive ability, and investigate the regulatory function of hsa-miR-574-5p on these processes.

Methods A549 cells with high and low CBR1 expression were established by transfection with a CBR1-pENTER plasmid and an hsa-miR-574-5p analog, respectively, MTT assays were performed to measure cell proliferation ability, RT-PCR and western blot were used to detect the expression of CBR1, and E-cadherin, and transwell migration assays were used to detect the invasive ability of the cells.

Results Cells transfected with CBR1-pENTER showed increased CBR1 and E-cadherin expression and reduced invasive ability; those transfected with hsa-miR-574-5p showed reduced CBR1 and E-cadherin expression and increased invasive ability. There was no significant difference in proliferation ability among the groups.

Conclusions In A549 cells, the expression of CBR1 is irrelevant to cell proliferation ability but affects invasive ability; hsa-miR-574-5p can enhance the invasive ability of cells by down regulating CBR1 expression; hsa-miR-574-5p may not only be biological marker for diagnosis, but also may be an important prognostic index for patients with non-small cell lung cancer.


Keywords


A549 cells, carbonyl reductase 1, hsa-miR-574-5p, invasive ability, non-small cell lung cancer

Full Text:

References


Malátková P, Maser E, Wsól V. Human carbonyl reductases. Curr Drug Metab. 2010;11:639–658.

Wu WS, Wu JR, Hu CT. Signal cross talks for sustained MAPK activation and cell migration. Cancer Metastasis Rev. 2008;27:303–314.

Baud V, Jacque E. The alternative nf-kb activation pathway and cancer: Friend or foe?. Med Sci (Paris). 2008;24:1083–1088.

Shen HM, Tergaonkar V. NfkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis. 2009;14:348–363.

Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, et al. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99(10):2045–2054.

López de Cerain A, Marín A, Idoate MA, Tuñón MT, Bello J. Carbonyl reductase and NADPH cytochrome p450 reductase activities in human tumoral versus normal tissues. Eur J Cancer. 1999;35:320–324.

Ismail E, Al-Mulla F, Tsuchida S, Suto K, Motley P, Harrison PR, et al. Birnie. Carbonyl reductase: a novel metastasis-modulating function. Cancer Res. 2000;60:1173–1176.

Suto K, Kajihara-Kano H, Yokoyama Y, Hayakari M, Kimura J, Kumano T, et al. Decreased expression of the peroxisomal bifunctional enzyme and carbonyl reductase in human hepatocellular carcinomas. J Cancer Res Clin Oncol. 1999;125:83–88.

Murakami A, Yakabe K, Yoshidomi K, Sueoka K, Nawata S, Yokoyama Y, et al. Decreased carbonyl reductase 1 expression promotes malignant behaviours by induction of epithelial mesenchymal transition and its clinical significance. Cancer Lett. 2012;323:69–76.

Takenaka K, Tanaka F, Ogawa E, Oyanagi H, Wada H. Carbonyl reductase expression and its clinical significance in nonsmall-cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1972–1975.

Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. Mir- 1254 and mir-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol.2011;6:482–488.

Kalabus JL, Cheng Q, Blanco JG. MicroRNAs differentially regulate carbonyl reductase 1 (CBR1) gene expression dependent on the allele status of the common polymorphic variant rs9024. PLoS One. 2012;7:e48622.

Schlager JJ, Powis G. Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol. Int J Cancer. 1990;45: 403–409.

Schieber A, Frank RW, Ghisla S. Purification and properties of prostaglandin 9-ketoreductase from pig and human kidney. Identity with human carbonyl reductase. Eur J Biochem.1992;206:491–502.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–198.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Journal of Pharmaceutical and Biomedical Sciences

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.